A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.

About the trial

Sponsor

Sanofi

Tested

TIV-HA Vaccine formulation 1 at low dose (biological), TIV-HA formulation 1 at high dose (biological), TIV-HA formulation 2 at low dose (biological), TIV-HA formulation 2 at high dose (biological), RSV/hMPV/PIV3 formulation 2 at low dose (biological), RSV/hMPV/PIV3 formulation 1 at high dose (biological), RSV/hMPV/PIV3 formulation 2 at high dose (biological), RSV/hMPV/PIV3 formulation 1 at low dose (biological), RIV4 (Supemtek®) (biological)

Dates

Started 2025-03-19; completion 2025-12-11

Results posted

Not yet

The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine in healthy participants 18 to 49 years of age. A lipid nanoparticle will be used in this study. Overall, the study is designed to: * Assess the safety profile of the candidate formulations * Describe the immunogenicity profile of the candidate formulations * Eligible participants will be randomized to receive a single intramuscular injection of either one of the vaccine formulations. Participants will be provided with a diary to so…

From ClinicalTrials.gov, last updated 2026-01-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi Pasteur Inc. reported $93,100 in research payments for this study in 2025 (2 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.